TX-BRS-LABS
GDT , a powerhouse of next-generation IT solution deployment and thought leadership, and Behavioral Recognition Systems (BRS Labs), a leader in multi-sensor data analytics, today announced a partnership that will help bring cutting-edge behavioral recognition technology to new markets.
According to the agreement, GDT will act as an authorized reseller of the BRS Labs award-winning AISight ® platform. AISight is a self-learning, multi-sensor data analytics solution that recognizes and alerts on abnormal patterns within massive volumes of data. AISight’s multi-sensor data analytics have many applications, including big data, Supervisory Control and Data Acquisition (SCADA), intelligent video analytics, Information Security (InfoSec), Building Management Systems (BMS), and other core business functions.
BRS Labs plans to leverage the global reach of GDT and their relationships with top tier companies in diverse vertical markets to bring AISight’s revolutionary technology to new customers in existing markets while exploring new big data applications. The deep Texas roots of GDT in oil and gas complement BRS Labs’ recent entrance into this market with the release of AISight for SCADA.
“We’re excited to announce our partnership with GDT,” said Keith Drummond , Executive Vice President of BRS Labs. “Our technology relationship with Cisco and the Cisco Gold Partner standing and triple master specializations of GDT allow us to jointly offer an integrated big data analytics solution unlike anything currently available on the market.”
GDT prides itself in designing and building imaginative solutions that align their client’s technology and business goals and strives to form partnerships with like-minded, leading innovators whose offerings benefit their existing and future clients as well. GDT cites the business functionality and maturity of AISight in raw data analytics with real-time proactive anomaly alerts for various data sets as exceeding expectations.
”BRS Labs first got our attention with the multi-functionality of AISight,” said Steve Sulgrove, GDT regional client manager. “Its artificial intelligence that doesn’t rely on dated rules-based technology, its relevance to the industries we serve and the new products and solutions we can offer our clients – that’s what made us realize this was an incredible opportunity we had to take advantage of.”
For more information about BRS Labs please visit www.BRSLabs.com .
For more information about GDT please visit www.gdt.com .
About BRS Labs
BRS Labs builds behavioral recognition software, using artificial intelligence-based technology, that teaches itself to recognize and alert on abnormal patterns within massive volumes of data. The AISight Everywhere™ platform is a centralized system with modules for big data, intelligent video analytics, SCADA, InfoSec, and other core business functions. BRS Labs is headquartered in Houston, with offices in Washington DC, London, Sao Paulo, and Barcelona.
Visit us on:
● YouTube
AISight® is a registered trademark, and Behavioral Recognition™ is a trademark of Behavioral Recognition Systems, Inc. Any other trademarks mentioned are the property of their owners.
About GDT
GDT is a technology integration partner with triple master Cisco specializations and a long list of awards that includes Cisco Architectural Excellence US: SP Architectures and Cisco Enterprise Partner of the Year for four consecutive years. Founded in 1996 and headquartered in Dallas, Texas, GDT has offices in the Northeast and on the West Coast of the US, as well as international offices in Australia, Canada, Hong Kong, India, Singapore, and the UK. GDT translates the latest ideas and technologies into inventive solutions that accelerate outcomes and realize the goals of IT and the vision of business leaders.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141111005049/en/
Contact:
BRS Labs
Jennifer Harrington, 713-590-5194
jharrington@brslabs.com
or
GDT
Darjon
Bittner
darjon.bittner@gdt.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum